Synonyms: GW597588B
Compound class:
Synthetic organic
Comment: Vestipitant is an investigational NK1 receptor antagonist.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Vestipitant has been investigated in Phase 2 clinical trials as potential antiemetic [4] and anxiolytic drug [1], and as a treatment for tinnitus and insomnia [3]. Click here to link to ClinicalTrials.gov's list of Phase 2 vestipitant trials, and here to access the GSK clinical study register details for this compound. |